NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

Core Points - NewGenIvf Group Limited has been granted continued listing on the Nasdaq Stock Market, subject to specific conditions [1][2] - The company has appointed Thorain Ko as Business Development Director to lead expansion initiatives, particularly in the lifetime egg-freezing business [1][3][5] Listing Update - The Nasdaq Hearings Panel approved NewGen's request for continued listing, contingent on meeting several conditions within specified time frames [2] - The company has made progress on its compliance plan, including a reverse stock split on February 11, 2025, and has achieved compliance with the minimum shareholders' equity requirement ahead of schedule [2] Management Appointment - Thorain Ko has been appointed as Business Development Director, bringing over 30 years of experience in business development and healthcare [3][4] - Mr. Ko's role will focus on developing the lifetime egg-freezing business in China and broader Asian markets, as well as driving sales initiatives across NewGen's fertility services [3][5] Company Overview - NewGen is a comprehensive fertility services provider in Asia, offering a range of treatments to help couples and individuals facing fertility challenges [6] - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing services such as assisted reproductive technology, egg and sperm donation, and surrogacy [6]